Companies /Healthcare

Novo Nordisk A/S

NYSE: NVO Drug Manufacturers - General
$41.60
▲ $0.95 (+2.32%) today
Markets open · 2:06pm ET

24/7 Wall St. View

Price Prediction $48.43 +19.1% Our analysts’ 12-month view: target, optimistic case, and floor. NVO price prediction →

NVO at a Glance

Valuation
Market cap
$181.1B
P/E ratio
10.4
Dividend yield
4.37%
Profitability
Revenue (TTM)
$333.7B
Profit margin
33.9%
EPS (TTM)
$3.96
Price
52-week range
$34 – $61
24/7 target
$48.43
Street target
$45.67

Headquartered in Novo Alle 1, Bagsvaerd Fiscal year ends December NYSE: NVO novonordisk.com

About Novo Nordisk

Novo Nordisk A/S is a global healthcare company focused on serious chronic diseases, with deep expertise in diabetes and obesity care. The company develops, manufactures, and markets a portfolio of GLP-1-based therapies including Ozempic, Wegovy, Rybelsus, and Victoza for diabetes and weight management, as well as Saxenda for obesity. Novo Nordisk also operates in rare disease therapeutics. The company's B shares trade on Nasdaq Copenhagen and its American Depositary Receipts (ADRs) trade on the New York Stock Exchange under the ticker NVO. Novo Nordisk employs approximately 66,700 people across 80 countries and markets its products in around 170 countries. The company's pipeline includes research into next-generation treatments for obesity and metabolic diseases, though its Q2 2026 filing noted a significant impairment of the monlunabant pipeline asset. Updated

Latest Activity

Jim Cramer@jimcramer

Cramer is calling a mispricing in the obesity drug race, arguing Lilly's latest wins over Novo Nordisk have not been paid for by the market yet.

LLY tons of powerful news versus Novo on weight loss drugs. Being ignored
  • Replies11
  • Reposts2
  • Likes41
Read more
Biggest movers · At the close
Gainers
  • ARMArm$323+17.2%
  • ALABAstera Labs$342.36+12.9%
  • APPSDigital Turbine$12.02+12.8%
  • INTCIntel$122.14+12.5%
  • DOCNDigitalOcean$146.28+12.4%
Losers
  • NVONovo Nordisk$39.81-7.9%
  • IOTSamsara$38.08-3.7%
  • XOMExxon Mobil$158.69-3.0%
  • CVXChevron$203.95-2.6%
  • BROSDutch Bros$39.05-2.5%

Arm closed up 17.19% at $323, topping a session where four other priority names each added more than 12%. Declines stayed shallow: Novo Nordisk's 7.94% drop was the only one past 4%, with Exxon Mobil and Chevron down under 3%.

Read more
House trade disclosureScott Scott Franklin
  • ACNAccenture plc Class A Ordinary Shares (ACN)Buy$1K – $15KAug 26
  • ACNAccenture plc Class A Ordinary Shares (ACN)Buy$1K – $15KAug 26
  • GOOGAlphabet Inc. - Class C Capital Stock (GOOG)Partial sell$1K – $15KAug 20
  • GOOGFidelity Roth IRA Alphabet Inc. - Class C Capital Stock (GOOG)Partial sell$1K – $15KAug 20
  • AAPLApple Inc. - Common Stock (AAPL)Partial sell$1K – $15KAug 20
  • JPMFidelity Roth IRA JP Morgan Chase & Co. Common Stock (JPM)Partial sell$1K – $15KAug 20
  • JPMJP Morgan Chase & Co. Common Stock (JPM)Partial sell$1K – $15KAug 20
  • LSYIXLord Abbett Short Duration High Yield I (LSYIX) bond fundBuy$1K – $15KAug 26
+ 4 more trades in this filing
Made public 28 days after the earliest trade

About as clear a risk-off tell as a House filing gives you: a sitting appropriator rotated out of megacap tech and a big bank in the same week. The filing shows trims of Alphabet, Apple and JPMorgan on Aug. 20, purchases of defensive names like McDonald's, PepsiCo and Novo Nordisk six days later, plus short duration high yield.

Read more

NVO Coverage

Load More

Frequently Asked Questions

What does Novo Nordisk do?

Novo Nordisk A/S is a global healthcare company focused on serious chronic diseases, with deep expertise in diabetes and obesity care.

What is the NVO stock price target?

24/7 Wall St.'s 12-month price target for NVO is $48.43, rated Buy. The Wall Street consensus target is $45.67. NVO price prediction →